10 September 2018 - The Scottish Medicines Consortium, has today published advice accepting four new medicines for use by NHSScotland. 

Two of the medicines were accepted through SMC’s Patient and Clinician Engagement (PACE) process, which is used to consider medicines for treating end of life and very rare conditions.

Tocilizumab (RoActemra) was accepted for the treatment of Giant Cell Arteritis (GCA) in adult patients. GCA is a rare condition in which arteries, usually of the head, are inflamed.

Also accepted through PACE was dupilumab (Dupixent). Dupilumab can be used to treat moderate to severe atopic dermatitis (also known as atopic eczema), a distressing and disabling long-term skin condition.

Read SMC press release